Bradford D. Gessner, M.D., M.P.H.

Vice President Global Medical Lead for Respiratory Vaccines
Pfizer Biopharma Group

Disclosure(s): Pfizer: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-8) Assessment of 13-valent pneumococcal conjugate vaccine effectiveness among people living with HIV in the United States
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-21) Comparison of Three RSV Vaccine Lower Respiratory Tract Disease Primary Endpoint Definitions for Adult Vaccine
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-40) Impact of case and control selection on influenza vaccine effectiveness (VE) among adults aged 40 years and older hospitalized with acute respiratory illness (ARI) during 2022-2023 using a test negative design (TND): secondary analysis of the North America multi-specimen study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-604) Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-677) Title: Estimation of Respiratory Syncytial Virus-attributable Hospitalizations among Older Adults in Japan between 2015 and 2018: an Administrative Health Claims Database Analysis
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-680) Estimated Respiratory Syncytial Virus (RSV)-Related Hospitalizations and Deaths among Adults in Norway between 2010–2019
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-681) Estimated Incidence of Respiratory Syncytial Virus (RSV)-related Hospitalizations for Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults in Germany
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-682) The Risk of Cardiorespiratory Events for up to 180 days Following Respiratory Syncytial Virus (RSV) Infection Hospitalization: A Self-controlled Case Series Analysis
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-683) Estimation of RSV-attributable cardiovascular and respiratory hospitalizations in adults in Germany between 2015–2019
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-2357) Respiratory Syncytial Virus (RSV) Disease Burden among Adults in Primary Care Settings in High-income Countries: a Systematic Review and Modelling Study
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT